Sensei Biotherapeutics (NASDAQ:FTH) CFO Brian Stephenson Purchases 5,000 Shares of Stock

Sensei Biotherapeutics, Inc. (NASDAQ:FTH) CFO Brian Stephenson acquired 5,000 shares of the company’s stock in a transaction that occurred on Wednesday, July 1st. The shares were acquired at an average cost of $23.50 per share, for a total transaction of $117,500.00. Following the completion of the transaction, the chief financial officer directly owned 46,688 shares of the company’s stock, valued at $1,097,168. The trade was a 11.99% increase in their ownership of the stock. The purchase was disclosed in a document filed with the SEC, which is available through this link.

Sensei Biotherapeutics Stock Down 5.4%

NASDAQ FTH opened at $23.66 on Thursday. Sensei Biotherapeutics, Inc. has a one year low of $6.32 and a one year high of $36.76. The stock has a market capitalization of $31.70 million, a P/E ratio of -0.17 and a beta of -0.26.

Sensei Biotherapeutics (NASDAQ:FTH) last posted its earnings results on Friday, May 15th. The company reported ($131.45) earnings per share (EPS) for the quarter. On average, sell-side analysts expect that Sensei Biotherapeutics, Inc. will post -16.61 EPS for the current year.

Analyst Ratings Changes

Several equities research analysts recently issued reports on FTH shares. HC Wainwright started coverage on shares of Sensei Biotherapeutics in a report on Monday, June 22nd. They issued a “buy” rating and a $60.00 target price on the stock. Weiss Ratings assumed coverage on Sensei Biotherapeutics in a report on Wednesday, June 17th. They set a “sell (d-)” rating on the stock. Robert W. Baird began coverage on Sensei Biotherapeutics in a research note on Friday, June 26th. They issued an “outperform” rating and a $57.00 price target on the stock. Finally, BTIG Research raised Sensei Biotherapeutics to a “strong-buy” rating in a report on Thursday, June 11th. Two analysts have rated the stock with a Strong Buy rating, one has issued a Buy rating and one has issued a Sell rating to the company. According to data from MarketBeat, the company currently has an average rating of “Buy” and an average target price of $58.50.

Sensei Biotherapeutics Company Profile

Sensei Biotherapeutics, Inc is a clinical-stage biotechnology company focused on developing next-generation immunotherapies for cancer. The company applies its proprietary ImmunoPhage platform to create conditionally active biologics designed to stimulate the immune system in the tumor microenvironment while limiting activity in healthy tissue.

Its product pipeline has included experimental therapies such as solnerstotug (formerly SNS-101), a checkpoint inhibitor targeting VISTA, and additional oncology candidates in earlier stages of development.